Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an update.
Genflow Biosciences Plc has made significant advancements in its SIRT6 programs, intellectual property, and strategic partnerships. The company signed a Master Service Agreement with CER Groupe to support its gene therapy programs and expanded its global intellectual property portfolio, with patents progressing in Europe and Japan. Genflow’s programs, including MASH, Werner Syndrome, dog aging, sarcopenia, and ophthalmology, are progressing well, supported by collaborations and grants. These developments enhance Genflow’s positioning in the biotechnology industry, potentially impacting stakeholders by advancing age-related disease treatments.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with R&D facilities in Belgium, specializing in gene therapies aimed at slowing the aging process. The company focuses on promoting longer and healthier lives while addressing the impacts of an aging global population. Genflow’s lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, showing promising preclinical results.
Average Trading Volume: 2,853,020
Technical Sentiment Signal: Sell
Learn more about GENF stock on TipRanks’ Stock Analysis page.